We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+73.06%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$912M
AUM Growth
-$156M
Cap. Flow
-$257M
Cap. Flow %
-28.19%
Top 10 Hldgs %
35.78%
Holding
190
New
54
Increased
34
Reduced
35
Closed
53

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.96M
2
CYTK icon
Cytokinetics
CYTK
+$8.91M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.6M
4
JBIO
Jade Biosciences
JBIO
+$8.03M
5
PYXS icon
Pyxis Oncology
PYXS
+$6.99M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$26.5M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$21.4M
3
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$19.1M
4
NUVL
Nuvalent
NUVL
+$12.5M
5
IRON icon
Disc Medicine
IRON
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 39.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
76
DELISTED
Ventyx Biosciences
VTYX
$2.79M 0.31%
507,647
+501,733
+8,484% +$2.29M
MRNS
77
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.74M 0.3%
+303,200
New +$2.95M
KOD icon
78
Kodiak Sciences
KOD
$2.6B
$2.51M 0.27%
476,586
+63,705
+15% +$312K
TRML
79
DELISTED
Tourmaline Bio
TRML
$2.48M 0.27%
+108,483
New +$3.83M
QURE icon
80
uniQure
QURE
$3.03B
$2.44M 0.27%
469,133
+311,768
+198% +$1.79M
IBIO icon
81
iBio
IBIO
$69.5M
$2.44M 0.27%
+600,000
New +$754K
NUVB icon
82
Nuvation Bio
NUVB
$2.2B
$2.31M 0.25%
633,282
-589,570
-48% -$1.13M
SGMT icon
83
Sagimet Biosciences
SGMT
$439M
$2.24M 0.25%
+412,565
New +$2.96M
RAPT
84
PUT
DELISTED
RAPT Therapeutics
RAPT
$2.21M 0.24%
30,775
+23,425
+319% +$3.26M
ATXS
85
PUT
DELISTED
Astria Therapeutics
ATXS
$2.16M 0.24%
+153,700
New +$1.91M
IMUX icon
86
Immunic
IMUX
$190M
$2.13M 0.23%
+161,238
New +$2.1M
APLS
87
DELISTED
Apellis Pharmaceuticals
APLS
$2.06M 0.23%
35,092
+731
+2% +$46.6K
ATXS
88
DELISTED
Astria Therapeutics
ATXS
$1.98M 0.22%
140,687
-234,120
-62% -$2.92M
INSM icon
89
PUT
Insmed
INSM
$21.4B
$1.92M 0.21%
+70,900
New +$1.98M
MRNS
90
PUT
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.92M 0.21%
+212,200
New +$2.06M
LENZ
91
LENZ Therapeutics
LENZ
$166M
$1.9M 0.21%
+85,000
New +$1.77M
ACHL
92
DELISTED
Achilles Therapeutics
ACHL
$1.8M 0.2%
+1,443,181
New +$1.56M
VYGR icon
93
Voyager Therapeutics
VYGR
$183M
$1.68M 0.18%
180,857
-125,000
-41% -$1.06M
IRON icon
94
Disc Medicine
IRON
$2.96B
$1.58M 0.17%
25,372
-169,610
-87% -$11M
BMEA icon
95
PUT
Biomea Fusion
BMEA
$84.6M
$1.54M 0.17%
103,000
-397,000
-79% -$6.54M
INSM icon
96
Insmed
INSM
$21.4B
$1.39M 0.15%
+51,335
New +$1.44M
RAPT
97
DELISTED
RAPT Therapeutics
RAPT
$1.39M 0.15%
+19,328
New +$2.69M
ITOS
98
DELISTED
iTeos Therapeutics
ITOS
$1.38M 0.15%
101,325
-245,146
-71% -$2.67M
PRAX icon
99
CALL
Praxis Precision Medicines
PRAX
$8.58B
$1.33M 0.15%
+21,800
New +$978K
ALLK
100
DELISTED
Allakos
ALLK
$1.18M 0.13%
932,675
+695,619
+293% +$1.08M
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Ikarian Capital held 190 positions worth $912M, down 15% from $1.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Ikarian Capital withdrew a net $257M in Q1 2024, closing 53 positions and reducing 35 holdings. Its most notable exit was argenx, an estimated $26.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 32% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Alnylam Pharmaceuticals worth $7.7M.

  • Ikarian Capital's largest Q1 2024 buy was Alnylam Pharmaceuticals: 51,541 shares worth $7.7M.
  • Ikarian Capital added most to Corbus Pharmaceuticals in Q1 2024, an estimated $8.96M increase.
  • Ikarian Capital's biggest Q1 2024 reduction was Longboard Pharmaceuticals, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited argenx in Q1 2024, selling an estimated $26.5M.
  • Ikarian Capital's ten largest holdings make up 36% of its $912M portfolio in Q1 2024.
  • Ikarian Capital opened 54 new positions and closed 53 in Q1 2024.
  • Ikarian Capital's portfolio value fell 15% quarter-over-quarter to $912M.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.